MedTrace Logo

3-year Study of Menostar Versus Evista to Prevent Osteoporosis in Post-menopausal Women

NCT00310531 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 500

Last updated 2014-12-30

No results posted yet for this study

Summary

The aim of this trial is to investigate whether the Menostar patch is as safe and effective in the prevention of bone loss in postmenopausal women as raloxifen, a drug already registered for prevention and treatment of osteoporosis.

Conditions

  • Osteopenia

Interventions

DRUG

Menostar (Estradiol, BAY86-5435)

Menostar (estradiol transdermal delivery system (SHP00577E), 0.014 mg/day)

DRUG

Raloxifene

Raloxifene tbl. (60 mg/day)

Sponsors & Collaborators

Principal Investigators

  • Bayer Study Director · Bayer

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
55 Years
Max Age
80 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-02-29
Completion
2007-06-30

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00310531 on ClinicalTrials.gov